A Elsharkawy1, R Fouad1, W El Akel1, M El Raziky1, M Hassany2, G Shiha3, M Said1, I Motawea4, T El Demerdash5, S Seif2, A Gaballah6, Y El Shazly7, M A M Makhlouf7, I Waked8, A O Abdelaziz1, A Yosry1, M El Serafy1, M Thursz9, W Doss1, G Esmat1. 1. Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. 2. Tropical Medicine Department, National Hepatology & Tropical Medicine Research Institute, Cairo, Egypt. 3. Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansora, Egypt. 4. Internal Medicine Department, Faculty of Medicine, Menia University, Minia, Egypt. 5. Tropical Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt. 6. Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt. 7. Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 8. Department of Hepatology, National Liver Institute, Menoufyia University, Menoufyia, Egypt. 9. Department of Hepatology, Imperial College London, London, UK.
Abstract
BACKGROUND: Chronic hepatitis C virus infection is one of the most important health problems in Egypt. The Ministry of Health's National Treatment Programme introduced sofosbuvir-based therapy in October 2014. AIM: To assess the clinical effectiveness and predictors of response to SOF-based treatment regimens, either dual therapy, with SOF/ribavirin (RBV) for 6 months or triple therapy with SOF/peg-IFN-alfa-2a/RBV for 3 months, in a cohort of patients treated in National Treatment Programme affiliated centres in Egypt. METHODS: Between October 2014 and end of 2014, patients who were eligible for treatment were classified according to their eligibility for interferon therapy: Group 1 (interferon eligible) were treated with triple therapy for 12 weeks and Group 2 (interferon ineligible) were treated with dual therapy for 24 weeks. Difficult to treat patients included those with F3-F4 on Metavir score, Fib-4 >3.25, albumin ≤3.5, total Bilirubin >1.2 mg/dL, INR >1.2 and platelet count <150 000 mm3 . RESULTS: Twelve weeks post-treatment data were available on 14 409 patients; 8742 in group 1 and 5667 in group 2. In group 1, the sustained virological response at week 12 (SVR12) was 94% and in group 2 the SVR12 was 78.7%. Multivariate logistic regression analysis in which treatment failure is the dependent variable was done. Male gender, being a difficult to treat patient and previous interferon therapy were significant predictors of nonresponse in both treatment groups. CONCLUSION: Results of sofosbuvir-based therapies in Egypt achieved similar rates of SVR12 as seen in phase III efficacy studies.
BACKGROUND:Chronic hepatitis C virus infection is one of the most important health problems in Egypt. The Ministry of Health's National Treatment Programme introduced sofosbuvir-based therapy in October 2014. AIM: To assess the clinical effectiveness and predictors of response to SOF-based treatment regimens, either dual therapy, with SOF/ribavirin (RBV) for 6 months or triple therapy with SOF/peg-IFN-alfa-2a/RBV for 3 months, in a cohort of patients treated in National Treatment Programme affiliated centres in Egypt. METHODS: Between October 2014 and end of 2014, patients who were eligible for treatment were classified according to their eligibility for interferon therapy: Group 1 (interferon eligible) were treated with triple therapy for 12 weeks and Group 2 (interferon ineligible) were treated with dual therapy for 24 weeks. Difficult to treat patients included those with F3-F4 on Metavir score, Fib-4 >3.25, albumin ≤3.5, total Bilirubin >1.2 mg/dL, INR >1.2 and platelet count <150 000 mm3 . RESULTS: Twelve weeks post-treatment data were available on 14 409 patients; 8742 in group 1 and 5667 in group 2. In group 1, the sustained virological response at week 12 (SVR12) was 94% and in group 2 the SVR12 was 78.7%. Multivariate logistic regression analysis in which treatment failure is the dependent variable was done. Male gender, being a difficult to treat patient and previous interferon therapy were significant predictors of nonresponse in both treatment groups. CONCLUSION: Results of sofosbuvir-based therapies in Egypt achieved similar rates of SVR12 as seen in phase III efficacy studies.
Authors: Abd Elrazek; Samy Saab; Mahmoud Foad; Elsayed A Elgohary; Mohammad M Sallam; Abdallah Nawara; Ali Ismael; Samar S Morsi; Altaher Salah; Mohamed Alboraie; Akshaya Srikanth Bhagavathula; Marwa Zayed; Hossam Elmasry; Tamer Z Salem Journal: J Transl Int Med Date: 2017-03-31
Authors: Hala Rady Ahmed; Nancy G F M Waly; Rehab Mahmoud Abd El-Baky; Ramadan Yahia; Helal F Hetta; Amr M Elsayed; Reham Ali Ibrahem Journal: PLoS One Date: 2021-04-15 Impact factor: 3.240
Authors: Kian Bichoupan; Neeta Tandon; James F Crismale; Joshua Hartman; David Del Bello; Neal Patel; Sweta Chekuri; Alyson Harty; Michel Ng; Keith M Sigel; Meena B Bansal; Priya Grewal; Charissa Y Chang; Jennifer Leong; Gene Y Im; Lawrence U Liu; Joseph A Odin; Nancy Bach; Scott L Friedman; Thomas D Schiano; Ponni V Perumalswami; Douglas T Dieterich; Andrea D Branch Journal: World J Virol Date: 2017-11-12